Cronos CEO Testifies on Short Selling Practices The recent testimony of Cronos CEO Mike Gonda has sparked intense scrutiny over short selling practices in the biotech sector.
As an industry leader, Cronos has been a subject of interest for investors and analysts, but beneath its high profile status lies a complex web of market dynamics, regulatory scrutiny, and accusations of unfair business practices.
Understanding Cronos CEO's Testimony on Short Selling Practices Short selling is a contentious issue that dates back to 18th century Amsterdam.